Serina Therapeutics Inc (SER) Income Statement
SER 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsSER revenue and net income
Where SER's revenue goes
2025Each bar shows an amount and its share of revenue. SER kept −14,755.4% of revenue as net income.
SER profit margins
SER growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +132.1% | −36.2% | +19.2% | — |
| Gross profit | — | −55.2% | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
SER quarterly EPS vs estimates
Serina Therapeutics beat the analyst EPS estimate in 3 of the last 7 quarters. Next report: November 12, 2026.
SER income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $130,000 | $56,000 | $3.2M | $500,000 | $3.5M | $54,000 | $1.7M | $1.4M | $1.4M | $1.7M |
| Cost of revenue | $85,000 | $194,000 | $90,000 | $145,000 | $3.8M | $1.3M | $998,500 | $841,000 | $685,000 | $911,000 |
| Gross profit | $45,000 | −$138,000 | $3.1M | $500,000 | −$333,840 | −$1.2M | $729,500 | $555,000 | $719,000 | $755,000 |
| Research & development | $13.2M | $7.5M | $2.4M | $1.6M | $3.8M | $3.6M | $5.3M | $5.4M | $5.3M | $7.9M |
| Sales, general & admin | $11.0M | $9.6M | $3.9M | $1.3M | $1.3M | — | — | — | — | — |
| Total operating expenses | $24.0M | $16.9M | $6.2M | $2.8M | $1.3M | $9.2M | $13.3M | $11.0M | $9.1M | $13.5M |
| Operating income | −$24.0M | −$17.0M | −$3.1M | −$2.3M | −$1.6M | −$10.4M | −$12.6M | −$10.4M | −$8.4M | −$12.7M |
| Interest income | $213,000 | $5.6M | $4.9M | $1,757 | $10,859 | — | — | — | — | — |
| Interest expense | $213,000 | $526,000 | $558,000 | $15,878 | $3,094 | $404,000 | — | — | $12,000 | $25,000 |
| Income before taxes | −$19.2M | −$11.2M | $5.3M | −$2.7M | −$1.3M | −$10.4M | −$12.2M | −$7.7M | −$6.6M | −$17.4M |
| Income taxes | $18,000 | — | −$8,000 | −$250,038 | $3,094 | $466,000 | $148,000 | −$229,000 | −$57,000 | −$1.9M |
| Net income | −$19.2M | −$11.1M | $5.3M | −$2.7M | −$1.3M | −$10.9M | −$12.2M | −$7.5M | −$6.6M | −$15.5M |
| EBITDA | −$18.9M | −$10.5M | $5.9M | −$2.6M | −$1.2M | −$8.7M | −$11.3M | −$7.2M | −$7.7M | −$11.9M |
| EPS (diluted) | −$1.97 | −$3.09 | −$13.72 | −$0.27 | −$0.23 | −$0.28 | −$0.33 | −$3.19 | −$6.46 | — |
| Gross margin | 34.6% | −246.4% | 97.1% | 100.0% | −9.6% | −2,272.2% | 42.2% | 39.8% | 51.2% | 45.3% |
| Operating margin | −18,478.5% | −30,442.9% | −99.2% | −454.1% | −47.1% | −19,272.2% | −726.8% | −748.2% | −599.5% | −764.6% |
| Net margin | −14,755.4% | −19,894.6% | 167.1% | −536.4% | −36.5% | −20,120.4% | −703.4% | −537.4% | −468.7% | −929.9% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $130,000 | $0 | $0 | $14,000 | $51,000 | $5,000 | $3.1M | $29,000 |
| Cost of revenue | — | $18,000 | $3.4M | $3.7M | $16,000 | $17,000 | $2.4M | $2.4M | $57,000 | $25,000 | $6,000 | $53,000 |
| Gross profit | — | −$18,000 | −$3.4M | −$3.7M | $114,000 | −$17,000 | −$2.4M | −$2.4M | −$6,000 | −$20,000 | $3.1M | −$24,000 |
| Research & development | $3.8M | $3.2M | $3.4M | $3.7M | $3.2M | $3.0M | $2.4M | $2.4M | $1.6M | $1.1M | $907,000 | $550,000 |
| Sales, general & admin | $3.0M | $3.1M | $2.6M | $2.7M | $2.5M | $2.9M | $1.5M | $2.9M | $2.3M | $1.2M | $1.9M | $889,000 |
| Total operating expenses | $6.8M | $6.3M | $2.8M | $2.7M | $5.7M | $5.9M | $3.2M | $2.9M | $3.9M | $2.3M | $2.8M | $1.4M |
| Operating income | −$6.8M | −$6.3M | −$6.2M | −$6.4M | −$5.6M | −$5.9M | −$5.5M | −$5.3M | −$3.9M | −$2.3M | $241,000 | −$1.5M |
| Interest income | — | — | $198,000 | $6,000 | $9,000 | $989,000 | — | $6.7M | $9.1M | — | — | — |
| Interest expense | $203,000 | $189,000 | $198,000 | $6,000 | $9,000 | $0 | $17,000 | $16,000 | $242,000 | $99,000 | $176,000 | $100,000 |
| Income before taxes | −$6.4M | −$6.9M | −$3.3M | −$4.6M | −$6.5M | −$4.8M | −$2.8M | $1.4M | $5.2M | −$15.0M | $1.1M | $1.8M |
| Income taxes | — | $7,000 | $18,000 | — | — | — | — | — | −$27,000 | $99,000 | −$2,000 | $12,000 |
| Net income | −$6.4M | −$6.9M | −$3.3M | −$4.6M | −$6.4M | −$4.8M | −$2.7M | $1.4M | $5.2M | −$15.0M | $1.1M | $1.8M |
| EBITDA | −$7.4M | −$7.1M | −$3.1M | −$4.6M | −$6.4M | −$4.8M | −$2.7M | $1.5M | $5.5M | −$14.8M | $1.2M | $1.9M |
| EPS (diluted) | −$0.55 | −$0.53 | −$0.31 | −$0.51 | −$0.66 | −$0.49 | −$0.36 | $0.13 | $0.51 | −$3.38 | −$3.20 | −$5.01 |
| Gross margin | — | — | — | — | 87.7% | — | — | −17,150.0% | −11.8% | −400.0% | 99.8% | −82.8% |
| Operating margin | — | — | — | — | −4,280.8% | — | — | −37,942.9% | −7,580.4% | −46,420.0% | 7.8% | −5,044.8% |
| Net margin | — | — | — | — | −4,960.0% | — | — | 10,071.4% | 10,203.9% | −300,300.0% | 34.0% | 6,041.4% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in SER's financial statements (latest annual report filed March 25, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
SER financial results
In fiscal year 2025 (ended December 31, 2025), Serina Therapeutics reported revenue of $0.1 million, up 132.1% from the year before. It had a net loss of $19.2 million, a net profit margin of −14,755.4%. Diluted earnings per share came to −$1.97. Over five years revenue grew at an average rate of 19.2% a year.
See the SER stock overview for the latest quote and news, or the SER chart for price history and technical indicators.
SER income statement FAQ
What is Serina Therapeutics's annual revenue?
Serina Therapeutics reported total revenue of $0.1 million for fiscal year 2025, which ended on December 31, 2025. That was up 132.1% from $0.1 million the previous year.
Is Serina Therapeutics profitable?
No. Serina Therapeutics reported a net loss of $19.2 million in fiscal 2025, a net profit margin of −14,755.4%; its operating margin was −18,478.5%.
What is Serina Therapeutics's gross margin?
Serina Therapeutics's gross margin was 34.6% in fiscal 2025: for every $100 of revenue, Serina Therapeutics kept $35 after the direct cost of its products and services.
How much does Serina Therapeutics spend on research and development?
Serina Therapeutics spent $13.2 million on research and development in fiscal 2025, 10,119.2% of revenue.
How fast is Serina Therapeutics growing?
Revenue grew 19.2% a year on average over the last five fiscal years, from $0.1 million to $0.1 million.
What are Serina Therapeutics's earnings per share?
Serina Therapeutics earned $-1.97 per diluted share in fiscal 2025, compared with $-3.09 a year earlier.
When will Serina Therapeutics report its next earnings?
Serina Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 12, 2026.
When does Serina Therapeutics's fiscal year end?
Serina Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 25, 2026.